pharmacologic agents for treatment of Parkinson's disease

From Aaushi
Jump to navigation Jump to search

Adverse effects

Notes

More general terms

More specific terms

References

  1. Prescriber's Letter 18(9): 2011 CHART: Comparison of Parkinson's Disease Drugs CHART: Parkinson's Disease Therapy Algorithm Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270920&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  3. 3.0 3.1 Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18712508
  4. 4.0 4.1 Stevens KN, Creanor S, Jeffery A et al Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease. A Randomized Clinical Trial. JAMA Neurol. Published online October 31, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36315128 https://jamanetwork.com/journals/jamaneurology/fullarticle/2797508